Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study.

Area of Science:

• Biomaterials science
• Regenerative medicine
• Pharmacology

Background:

• Statins (HMG-CoA reductase inhibitors) are commonly used for hyperlipidemia.
• Previous research indicates statins can stimulate bone morphogenetic protein-2 (BMP-2) expression, promoting bone formation.
• A novel delivery system for percutaneous statin injection was developed.

Purpose of the Study:

• To evaluate the efficacy of percutaneously injected fluvastatin using a novel delivery system for vertical bone augmentation.
• To assess the impact of fluvastatin on new bone thickness and bone density.

Main Methods:

• Fluvastatin (low and high doses) was incorporated into atelocollagen-alpha-tricalcium phosphate (alphaTCP) composites.
• These composites were injected subcutaneously over the calvarial periosteum in rats.
• Bone augmentation was assessed via histomorphometry, measuring new bone thickness (NBT) and bone density (BD) at 1, 2, and 4 weeks.

Main Results:

• Experimental groups showed significant new bone formation over existing calvarial bone, directly contacting it.
• New bone thickness (NBT) was significantly increased in fluvastatin-treated groups compared to controls (P<0.05).
• At 4 weeks, NBT reached 66.7% (low dose) and 59.7% (high dose), with bone density increasing in a time-dependent manner.

Conclusions:

• Percutaneously administered fluvastatin via an alphaTCP and collagen composite shows significant potential for bone height augmentation.
• A single injection of fluvastatin with this delivery system effectively promotes bone formation.
• This method offers a promising approach for bone augmentation procedures.